Ret Mutation Positive Medullary Thyroid Cancer Therapeutics
1. Gavreto patent expiration
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatri...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10030005 | RIGEL PHARMS | Inhibitors of RET |
Nov, 2036
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11273160 | RIGEL PHARMS | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(13 years from now) | |
| US11872192 | RIGEL PHARMS | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(13 years from now) | |
| US11963958 | RIGEL PHARMS | RET inhibitor for use in treating cancer having a RET alteration |
Apr, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
| Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
| Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Dosage: CAPSULE
More Information on Dosage
GAVRETO family patents
